A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
Docetaxel and vinorelbine are well known active agents in the treatment of NSCLC. The
standard treatment of elderly patients with advanced NSCLC is monotherapy with a third
generation agent. The role of comprehensive geriatric assessment in treatment efficacy and
tolerance is an area of investigation.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival between the two treatment arms
1 year
No
Lampros Vamvakas, MD
Principal Investigator
University Hospital of Crete, Department of Medical Oncology
Greece: National Organization of Medicines
CT/03.07
NCT00441922
January 2003
January 2008
Name | Location |
---|